AAAAAA

   
Results: 1-9 |
Results: 9
Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study
Authors: Chaix, C Grenier-Sennelier, C Clevenbergh, P Durant, J Schapiro, JM Dellamonica, P Durand-Zaleski, I
Citation: C. Chaix et al., Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study, J ACQ IMM D, 24(3), 2000, pp. 227-231
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan
Authors: DeGruttola, V Dix, L D'Aquila, R Holder, D Phillips, A Ait-Khaled, M Baxter, J Clevenbergh, P Hammer, S Harrigan, R Katzenstein, D Lanier, R Miller, M Para, M Yerly, S Zolopa, A Murray, J Patick, A Miller, V Castillo, S Pedneault, L Mellors, J
Citation: V. Degruttola et al., The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan, ANTIVIR TH, 5(1), 2000, pp. 41-48
Persisting long-term benefit of genotype-guided treatment for HIV-infectedpatients failing HAART. The Viradapt study: week 48 follow-up
Authors: Clevenbergh, P Durant, J Halfon, P del Giudice, P Mondain, V Montagne, N Schapiro, JM Boucher, CAB Dellamonica, P
Citation: P. Clevenbergh et al., Persisting long-term benefit of genotype-guided treatment for HIV-infectedpatients failing HAART. The Viradapt study: week 48 follow-up, ANTIVIR TH, 5(1), 2000, pp. 65-70
Multiples aspects of VIH resistance to antiretroviral drugs.
Authors: Clevenbergh, P Durant, J Garraffo, R Chaillou, S Cua, E Dellamonica, P
Citation: P. Clevenbergh et al., Multiples aspects of VIH resistance to antiretroviral drugs., MED MAL INF, 30(9), 2000, pp. 551-564
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the ViradaptStudy
Authors: Durant, J Clevenbergh, P Garraffo, R Halfon, P Icard, S Del Giudice, P Montagne, N Schapiro, JM Dellamonica, P
Citation: J. Durant et al., Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the ViradaptStudy, AIDS, 14(10), 2000, pp. 1333-1339
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients
Authors: Saves, M Raffi, F Clevenbergh, P Marchou, B Waldner-Combernoux, A Morlat, P Le Moing, V Riviere, C Chene, G Leport, C
Citation: M. Saves et al., Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients, ANTIM AG CH, 44(12), 2000, pp. 3451-3455
Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia
Authors: Byl, B Clevenbergh, P Jacobs, F Struelens, MJ Zech, F Kentos, A Thys, JP
Citation: B. Byl et al., Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia, CLIN INF D, 29(1), 1999, pp. 60-66
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial
Authors: Durant, J Clevenbergh, P Halfon, P Delgiudice, P Porsin, S Simonet, P Montagne, N Boucher, CAB Schapiro, JM Dellamonica, P
Citation: J. Durant et al., Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial, LANCET, 353(9171), 1999, pp. 2195-2199
Long term effectiveness of Saquinavir and Ritonavir low dosage (baby-dose)in HIV patients failing combination therapy: correlation of response to treatment with genotype mutations and pharmacological data
Authors: Chaillou, S Durant, J Clevenbergh, P Rahelinirina, V Garraffo, R Schapiro, JM Dellamonica, P
Citation: S. Chaillou et al., Long term effectiveness of Saquinavir and Ritonavir low dosage (baby-dose)in HIV patients failing combination therapy: correlation of response to treatment with genotype mutations and pharmacological data, SEVENTH EUROPEAN CONFERENCE ON CLINICAL ASPECTS AND TREATMENT OF HIV-INFECTION, 1999, pp. 69-72
Risultati: 1-9 |